CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

  • Parties intend to jointly enable AAV production in CEVEC’s CAP®GT cells in combination with PlasmidFactory’s broad AAV serotype plasmid portfolio
  • Collaboration will significantly increase the value of CAP®GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications

Cologne, Germany, May 11, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and service provider for plasmid and minicircle DNA.

The collaboration will allow CEVEC access to PlasmidFactory’s broad portfolio of AAV helper and packaging plasmids of the pDG family. The pDG plasmids support transfection of cells for AAV production, where the essential viral helper and packaging functions are located on only one plasmid, greatly facilitating the production of high AAV titers.

CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

  • Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP®GT technology
  • Collaboration is next step in setting CAP®GT as global standard in adenoviral gene therapy

Cologne, Wedel and Hamburg, Germany, March 16, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications.

CEVEC licenses CAP® technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP® technologies as the new global industrial standard for viral vector and vaccine development

Cologne, Germany, February 9, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP®GT and CAP®Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.

CEVEC submits Biologics Master File (BB-MF) for CAP® Technology to the U.S. FDA

  • Submission represents an important step towards establishing CAP®GT and CAP®Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production.
  • CEVEC’s CAP® technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP®-derived product.

Cologne, Germany, October 27, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that is has submitted a Biologics Master File (BB-MF) for its human cell substrate CAP® to the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER).

CEVEC further strengthens organization to drive industrialization and commercialization of CAP® technologies

  • Life sciences industry veteran Bart Bergstein to join CEVEC’s Supervisory Board
  • Two newly formed Scientific Advisory Boards for CEVEC’s CAP®GT and CAP®Go technologies will further drive industrialization

Cologne, Germany, June 29, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress.

CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP® technologies in North America

  • Agreement establishes Paragon as CEVEC’s preferred partner for contract development and manufacturing (CDMO) services in North America
  • Companies will conduct coordinated marketing and business development activities to establish CEVEC’s CAP® technologies as a new standard for gene therapy vector production
  • Collaboration includes developing a scalable clinical production process for AAV-based gene therapy vectors based on the CAP®GT platform

Cologne, Germany and Baltimore, MD, USA, June 6, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors and Paragon Bioservices, Inc., a leader in the manufacturing of biopharmaceuticals and vaccines, today announced that the companies signed a collaboration and license agreement to jointly establish CEVEC’s proprietary CAP® technologies as a new industry standard for the scalable production of viral gene therapy vectors in North America.

CEVEC’s CAP®GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications

  • CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
  • CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vectors

Cologne, Germany, May 10, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs.

CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US

Cologne, Germany, February 22, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications.

CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP®GT technology

  • CEVEC’s CAP®GT technology enables fully scalable lentiviral and RCA (replication competent adenovirus)-free adenoviral vector production
  • Further step to establish CEVEC’s CAP®GT technology as the industrial standard for the production of lentiviral and adenoviral gene therapy vectors

Cologne, Germany, January 20, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Beckman Research Institute of City of Hope (“Beckman Research Institute”) on CEVEC’s proprietary CAP®GT technology.

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies

  • CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies
  • CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing
  • BioLamina to further grow its leading high quality ex vivo cell culture laminin product portfolio
  • First commercial CAP®Go-derived laminin, LN-521, expected to be globally available in 2016

Cologne, Germany and Stockholm, Sweden, October 28, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and BioLamina AB, a leading manufacturer of high quality products for primary cell culture, announced today a strategic collaboration  …

CEVEC strengthens team to execute rapid growth strategy

  • Dr. Nico Scheer appointed as Vice President Business Development Glycoproteins
  • Dr. Hartmut Tintrup appointed as Vice President Business Development Gene Therapy and Viruses
  • Headcount increased by 40% since May 2015

Cologne, Germany, October 14, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the expansion and reorganization of its management team.

CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP®GT technology

  • Agreement enables fully scalable, industrial lentivirus vector production
  • Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications

Cologne, Germany, September 17, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC’s proprietary CAP®GT technology.

CEVEC introduces CAP®GT cell-expression system for scalable
viral gene therapy vector production

Cologne, Germany, September 7, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the introduction of its unique cell-expression system, CAP®GT for the fully scalable production of gene therapy vectors, based on the Company’s proprietary CAP® technology.

CEVEC raises € 4.5 million in a financing round to commercialize its leading CAP® based technologies

  • New and existing investors participated in this financing round
  • CEVEC is setting new industry standards in glyco-optimized protein and gene therapy vector production with proprietary CAP®Go and CAP®GT technologies

Cologne, Germany, July 22, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful completion of a financing round of € 4.5 million. New investors included Investtodate GmbH, Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC. Existing investors also participated in this financing. These included Peppermint VenturePartners GmbH, Creathor Venture Management GmbH, NRW.Bank, KfW Bank, G.A.T. Holding as well as a number of private individuals.

CEVEC’s CAP®Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study

  • New CAP®Go cell line for the production of glyco-optimized recombinant human alkaline phosphatase successfully established
  • CAP®Go derived recombinant human alkaline phosphatase optimized to address therapeutic needs in chronic inflammatory indications and neurodegenerative diseases

Cologne, Germany, July 6, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins, today announced the results of a preclinical animal study in which its CAP®Go derived recombinant placental human alkaline phosphatase (PLAP) showed significantly prolonged serum-half-life.

CEVEC grants license to Biotest AG for production of tailor-made glycoproteins

Cologne, Germany, July 1, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.

CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS

Cologne, Germany, June 1, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.

CEVEC ANNOUNCES APPOINTMENT OF
LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS
AS CHIEF EXECUTIVE OFFICER

Cologne, Germany, April 17, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.

CEVEC: CAP® DERIVED RECOMBINANT C1 INHIBITOR MATCHES BERINERT® IN ANIMAL STUDY

Cologne, Germany, February 2, 2015

CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).
CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than …

CEVEC INTRODUCES CMO SERVICES
FOR THE cGMP MANUFACTURING OF CAP-BASED
CLINICAL MATERIALS

Cologne, Germany, September 23, 2014

CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.